Rapid infectious killers

Emergency Medicine Clinics of North America

Volumn 22, Issue 4 SPEC. ISS., 2004, Pages 1099-1115

  Schneider, Jeffrey I ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT PROTEIN; RIFAMPICIN; SULTAMICILLIN; VANCOMYCIN;

BACTEREMIA; BACTERIAL MENINGITIS; BIOPSY; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CLOSTRIDIUM; DEBRIDEMENT; DRUG PENETRATION; ESCHERICHIA COLI; FEVER; FOURNIER GANGRENE; GAS GANGRENE; GRAM NEGATIVE SEPSIS; HAEMOPHILUS INFLUENZAE; HEADACHE; HEARING LOSS; HUMAN; IMMUNE RESPONSE; INCIDENCE; LABORATORY TEST; LISTERIA MONOCYTOGENES; LOBAR PNEUMONIA; MENINGISM; NECROTIZING FASCIITIS; NEISSERIA MENINGITIDIS; NUTRITIONAL SUPPORT; PATHOGENESIS; PENICILLIN RESISTANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEUS; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

EID: 5044226002     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2004.05.007     Document Type: Review

References (86)

1. Plaut G. The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol. 37:1983;603-622
2. Quagliarello V., Scheld W.M. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med. 327:1992;864-872
3. Fearon D.T. Regulation by membrane sialic acid of β1H-dependent decay dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 75:1978;1971-1975
4. Quagliarello V.J., Wispelwey B., Long W.J. Jr. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: characterization and comparison with tumor necrosis factor. J Clin Invest. 87:1991;1360-1366
5. Tuomanen E., Tomasz A., Hengstler B., Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis. 151:1985;535-540
6. Wenger J.D., Hightower A.W., Facklam R.R., Gaventa S., Broome C.V. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis. 162:1990;1316-1323
7. Cochi S.L., Broome C.V., Hightower A.W. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 253:1985;521-529
8. Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold A.L., et al. Bacterial meningitis in the United States in 1995. N Engl J Med. 337:1997;970-976
9. Gray B.M., Converse G.M.D., Dillon H.C. Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 142:1980;923-933
10. Wallace R.J., Musher D.M., Septimus E.J., McGowan J.E. Jr., Quinones F.J., Wiss K., et al. Haemophilus influenzae infections in adults: characteristics of strains by serotypes, biotypes, and beta-lactamase production. J Infect Dis. 144:1981;101-106
11. Spach D.H., Jackson L.A. Central nervous system infections. Neurol Clin. 17:1999;711-735
12. Butler J.C., Hofman J., Cetron M.S., Elliott J.A., Facklam R.R., Breiman R.F. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis. 174:1996;986-993
13. Doern G.V., Brueggemann A., Holley H.P. Jr., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 40:1996;1208-1213
14. Thornsberry C, Hickey M, Diakun D, et al. Sequential surveillance of antimicrobial resistance in the United States:Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (1997-1998 vs. 1996-1997). In 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA (September 24-27, 1998).
15. Friedland I.R., McCracken G.H. Jr. Management of infections caused by antibiotic resistant Streptococcus pneumoniae. N Engl J Med. 331:1994;377-382
16. Viladrich P.F., Gudiol F., Linares J., Pallares R., Sabate I., Rufi G., et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 35:1991;2467-2472
17. Doern G.V., Brueggemann A.B., Pierce G., Holley H.P. Jr., Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 41:1997;292-297
18. Woods C.R., Smith A.L., Wasilauskas B.L., Campos J., Givner L.B. Invasive disease caused by Neisseria meningitides relatively resistant to penicillin in North Carolina. J Infect Dis. 170:1994;453-456
19. Hieber J.P., Nelson J.D. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med. 297:1977;410-413
20. Analysis of endemic menigococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis. 134:1976;20-24
21. Control and prevention of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 46:1997;1-10
22. McIntyre P.B., Berkey C.S., King S.M., Schaad U.B., Kilpi R., Kanra G.Y., et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA. 278:1997;925-931
23. De Gans J., van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 347:2002;1549-1556
24. Berman P.H., Banker B.Q. Neonatal meningitis: a clinical and pathological study of 29 cases. Pediatrics. 38:1996;6-24
25. Pong A., Bradley J.S. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am. 13:1999;711-733
26. Chapnick E.K., Abter E.I. Necrotizing soft-tissue infections. Infect Dis Clin North Am. 10:1996;835-855
27. Giuliano A., Lewis F. Jr., Hadley K., Blaisdell F.W. Bacteriology of necrotizing fasciitis. Am J Surg. 134:1977;52-57
28. Casali R.E., Tucker W.E., Petrino R.A., Westbrook K.C., Read R.C. Postoperative necrotizing fasciitis of the abdominal wall. Am J Surg. 140:1980;787-790
29. Dahl P.R., Perniciaro C., Holmkvist K.A., O'Connor M.I., Gibson L.E. Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in seven patients. J Am Acad Dermatol. 47:2002;489-492
30. Swartz M.N. Cellulitis and subcutaneous tissue infections. Mandell G.L., Benne H., Dolin R. Practice of infectious diseases. 4th edition :1995;Churchill Livingstone, New York
31. Brook I., Frazier E.H. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol. 33:1995;2382
32. Stevens D.L., Tanner M.H., Winship J., Swarts R., Ries K.M., Schlievert P.M., et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin. N Engl J Med. 321:1989;1-7
33. Davies H.D., McGeer A., Schwartz B., Green K., Cann D., Simor A.E., et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 335:1996;547-554
34. Wolf J.E., Rabinowitz L.G. Streptococcal toxic shock-like syndrome. Arch Dermatol. 131:1995;73-77
35. Wilson H.D., Haltalin K.C. Acute necrotizing fasciitis in childhood: report of eleven cases. Am J Dis Child. 125:1973;591-595
36. Fisher J.R., Conway M.J., Takeshita R.T., Sandoval M.R. Necrotizing fasciitis: importance of roentgenographic studies for soft-tissue gas. JAMA. 241:1979;803-806
37. Sudarsky L.A., Laschinger J.C., Coppa G.F., Spencer F.C. Improved results from a standardized approach to treating patients with necrotizing fasciitis. Ann Surg. 206:1987;661-665
38. Majeski J.A., Alexander J.W. Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am J Surg. 145:1983;784-787
39. Mathieu D., Neviere R., Teillon C., Chagnon J.L., Lebleu N., Wattel F. Cervical necrotizing fasciitis: clinical manifestations and management. Clin Infect Dis. 21:1995;51-56
40. Pessa M.E., Howrad R.J. Necrotizing fasciitis. Surg Gynecol Obstet. 161:1985;357-361
41. Wilson B. Necrotizing fasciitis. Am Surg. 18:1952;416
42. Rouse T.M., Malangoni M.A., Schulte W.J. Necrotizing fasciitis: a preventable disaster. Surgery. 92:1982;765-770
43. Stamenkovik I., Lew D. Early recognition of potentially fatal necrotizing fasciitis: the use of frozen section biopsy. N Engl J Med. 310:1984;1689-1693
44. Francis K.R., Lamaute H.R., Davis J.M., Pizzi W.F. Implications of risk factors in necrotizing fasciitis. Am Surg. 59:1993;304-308
45. Rea W.J., Wyrick W.J. Jr. Necrotizing fasciitis. Ann Surg. 172:1970;957-964
46. Oh C., Lee C., Jacobson J.H. II. Necrotizing fasciitis of the perineum. Surgery. 91:1982;49-51
47. Hart G.B., Lamb R.C., Straus M.B. Gas gangrene. J Trauma. 23:1983;991-1000
48. Chin R.L., Martinez R., Garmel G. Gas gangrene from subcutaneous insulin administration. Am J Emerg Med. 11:1993;622-625
49. Hallagan L.F., Scott J.L., Horowitz B.C., Feied C.F. Clostridial myonecrosis resulting from subcutaneous epinephrine suspension injection. Ann Emerg Med. 21:1992;434-436
50. Kornbluth A.A., Danzig J.B., Bernstein L.H. Clostridium septicum infections and associated malignancy. Medicine. 68:1989;30-37
51. Weinstein L., Barza M.A. Gas gangrene. N Engl J Med. 289:1973;1129-1133
52. McDonel J.L. Clostridium perfringens toxins (type A, B, C, D, E). Pharmacol Ther. 10:1980;617-655
53. Demello F.J., Haglin J.J., Hitchcock C.R. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery. 73:1973;936-941
54. Morpurgo E., Galandiuk S. Fournier's gangrene. Surg Clin North Am. 82:2002;1213-1224
55. Yaghan R.J., Al-Jaberi T.M., Bani-Hani I. Fournier's gangrene: Changing face of the disease. Dis Colon Rectum. 43:2000;1300-1308
56. Gerber G.S., Guss S.P., Pielet R.W. Fournier's gangrene secondary to intra-abdominal processes. Urology. 44:1994;779-782
57. Gamagami R.A., Mostafavi M., Gamagami A., Lazorthes F. Fournier's gangrene: An unusual presentation for rectal carcinoma. Am J Gastroenterol. 93:1998;657-658
58. Brings H.A., Matthews R., Brinkman J., et al. Crohn's disease presenting with Fournier's gangrene and enterovesical fistula. Am Surg. 63:1997;401-405
59. Olsofka J.N., Carrillo E.H., Spain D.A., et al. The continuing challenge of Fournier's gangrene in the 1990's. Am Surg. 65:1999;1156-1159
60. Lazaron V., Barke R.A. Gram negative bacterial sepsis and the sepsis syndrome. Urol Clin North Am. 26:1999;687-699
61. Perl T., Dvorak L., Hwang T., Wenzel R.P. Long-term survival and function after suspected gram negative sepsis. JAMA. 274:1995;338-345
62. Bone R.C. Gram-negative sepsis: background, clinical features, and intervention. Chest. 100:1991;802-808
63. Michie H., Spriggs D., Manogue K., et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human being. Surgery. 104:1988;280-286
64. Centers for Disease Control. Increase in national hospital discharge rates for septicemia - United States. MMWR Morb Mortal Wkly Rep. 39:1990;31-34
65. Bernard G.R., Vincent J.-L., Laterre P.-F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709
66. Warren H.S., Suffredini A.F., Eichacker P.Q., Munford R.S. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 347:2002;1027-1030
67. Bartlett J.G., Dowell S.F., Lionel M.A., File T.M. Jr., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382
68. Austrian R. Life with the pneumococcus: notes from the bedside, laboratory, and library. 1985;University of Pennsylvania Press, Philadelphia
69. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 46:1997;1
70. Simberkoff M.S., Cross A.P., Al-Ibrahim M., Baltch A.L., Geiseler P.J., Nadler J., et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration cooperative study. N Engl J Med. 315:1986;1318-1327
71. Fine M.J., Smith M.A., Carson C.A., et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med. 154:1994;2666-2677
72. Doern G.V., Pfaller M.A., Kugler K., Freeman J., Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 27:1998;764-770
73. Kaplan S.L., Mason E.O. Jr. Management of infections due to antibiotic resistant Streptococcus pneumoniae. Clin Microbiol Rev. 11:1998;628-644
74. Amsden G.W. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother. 44:1999;1-6
75. Chen D.K., Mcgeer A., De Azavedo J.C., et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 34:1999;233-239
76. Bartlett J.G., Bartlett J.G., Dowell S.F., Lionel M.A., File T.M. Jr., Musher D.M., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382
77. Hayes C.G. West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci. 951:2001;25-37
78. Nash D., Mostashari F., Fine A., Miller J., O'Leary D., Murray K., et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 344:2001;1807-1814
79. Provisional surveillance summary of the West Nile virus epidemic - United States, January-November 2002. MMWR Morb Mortal Wkly Rep. 51:2002;1129-1133
80. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 286:1999;2333-2337
81. West Nile virus infection in organ donor and transplant recipients - Georgia and Florida. MMWR Morb Mortal Wkly Rep. 51:2002;790
82. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep. 51:2002;879
83. Intrauterine West Nile virus infection - New York. MMWR Morb Mortal Wkly Rep. 51:2002;1135
84. Laboratory-acquired West Nile virus infections - United States. MMWR Morb Mortal Wkly Rep. 51:2002;1133
85. Petersen L.R., Marfin A.A. West Nile virus: a primer for the clinician. Ann Intern Med. 137:2002;173-179
86. Pepperell C., Rau N., Krajden S., Kern R., Humar A., Mederski B. West Nile virus infection in 2002: Morbidity and mortality among patients admitted to hospital in south-central Ontario. Can Med Assoc J. 168:2003;1399-1405